Healthy Clinical Trial
Official title:
A Phase Ib Study to Confirm the Pharmacokinetics and Melanogenic Potential of Controlled-Release Bioresorbable Implants of Afamelanotide in Healthy Volunteers
NCT number | NCT03634137 |
Other study ID # | CUV028 |
Secondary ID | |
Status | Completed |
Phase | Phase 1 |
First received | |
Last updated | |
Start date | September 2009 |
Est. completion date | March 2010 |
Verified date | August 2018 |
Source | Clinuvel Pharmaceuticals Limited |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a single center, pharmacokinetic and pharmacodynamic study in healthy volunteers.
Twenty four subjects will be enrolled in the study and will be assigned to receive either a
16 mg afamelanotide bioresorbable implant from the current manufacturing process or a 16 mg
afamelanotide bioresorbable implant from the optimized manufacturing process. Implants will
be administered subcutaneously.
The following procedures will be conducted throughout the study:
- Collection of blood samples for analysis of afamelanotide concentrations
- Measurement of skin reflectance for estimation of melanin density, and luminance (L*),
blue/yellow colour hue (b*)
- Safety monitoring
Status | Completed |
Enrollment | 24 |
Est. completion date | March 2010 |
Est. primary completion date | February 2010 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: - Healthy Caucasian adults aged between 18 and 45 years (inclusive). - Free of significant abnormal findings as determined during the screening procedure by surgical and medical history, physical examination, ECG, clinical laboratory testing and vital signs. - BMI between 18 and 30 kg/m2 (inclusive). - No history of drug abuse, licit or illicit (including alcohol). - Agree not to use any medications (prescribed medicines, over-the-counter medications, dietary supplements or nutraceuticals) without pre-approval by the Principal Investigator or nominee during the 7 days preceding the study, and during the course of the study (until Day 60) - Willing to take precautions to prevent pregnancy until completion of the study (Day 60). - Able to understand and sign the written Informed Consent Form. - Able and willing to follow the Protocol requirements, including refraining from the use of melanogenic (tanning) products and recreational sun or UV light exposure from the start of the study until Day 60 Exclusion Criteria: - Any significant history of allergy and/or sensitivity to any of the contents of study drug product. - Any significant history of allergy and/or sensitivity to lignocaine or other local anaesthetic. - Any evidence of organ dysfunction or any clinically significant deviation from normal in the physical or clinical determinations. - Personal history of melanoma, dysplastic nevus syndrome or family history of melanoma in a first degree relative. - Any evidence at the screening medical examination of hypertension or hypotension. Hypertension is defined as three separate readings that persistently read over 140/90 mmHg systolic/diastolic. Hypotension is defined as three separate readings that persistently read under 90/50 mmHg systolic/diastolic. - A pulse rate of less than 50 beats/minute. - Any significant illness during the 4 weeks before the study screening period. - Any contraindication to blood sampling. - Any factor that may interfere with the skin reflectance measurements (e.g. vitiligo, albinism, excessive number of moles, or excessively hairy skin). - Positive screening urine drugs of abuse test. - Participation in any clinical study during the 4 weeks before the study screening period. - Has donated 400 mL or more of blood or had significant blood loss during the 8 weeks preceding screening. - Has donated plasma within the 7 days preceding screening. - Have consumed alcohol during the 24 hours prior to Day 1 |
Country | Name | City | State |
---|---|---|---|
United States | Prism Research Inc. | Saint Paul | Minnesota |
Lead Sponsor | Collaborator |
---|---|
Clinuvel Pharmaceuticals Limited |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in skin melanin density | To confirm serial changes in skin melanin density by reflectance spectrophotometry following administration of the final formulation afamelanotide bioresorbable implants in healthy volunteers. | 120 days | |
Secondary | Change in plasma concentrations of afamelanotide | To confirm the pharmacokinetics of afamelanotide by assessing afamelanotide plasma concentration following administration of the final formulation afamelanotide bioresorbable implants in healthy volunteers. | 60 days | |
Secondary | Number of Adverse Events | To confirm the tolerance of afamelanotide by assessing adverse events following administration of the final formulation afamelanotide implants in healthy volunteers. | 60 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |